337 related articles for article (PubMed ID: 30444747)
41. Vismodegib for treatment of periocular basal cell carcinoma - 6-year experience from a tertiary cancer center.
Xavier C; Lopes E; Bexiga C; Moura C; Gouveia E; Duarte AF
An Bras Dermatol; 2021; 96(6):712-716. PubMed ID: 34518037
[TBL] [Abstract][Full Text] [Related]
42. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management.
Le Moigne M; Saint-Jean M; Jirka A; Quéreux G; Peuvrel L; Brocard A; Gaultier A; Khammari A; Darmaun D; Dréno B
Support Care Cancer; 2016 Apr; 24(4):1689-95. PubMed ID: 26416491
[TBL] [Abstract][Full Text] [Related]
43. A Novel Alternate Dosing of Vismodegib for Treatment of Patients With Advanced Basal Cell Carcinomas.
Becker LR; Aakhus AE; Reich HC; Lee PK
JAMA Dermatol; 2017 Apr; 153(4):321-322. PubMed ID: 28114606
[No Abstract] [Full Text] [Related]
44. Management of high-risk and advanced basal cell carcinoma.
Puig S; Berrocal A
Clin Transl Oncol; 2015 Jul; 17(7):497-503. PubMed ID: 25643667
[TBL] [Abstract][Full Text] [Related]
45. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
[TBL] [Abstract][Full Text] [Related]
46. Periocular Mohs micrographic surgery in Western Australia 2009-2012: A single centre retrospective review and proposal for practice benchmarks.
O'Halloran L; Smith H; Vinciullo C
Australas J Dermatol; 2017 May; 58(2):106-110. PubMed ID: 26767931
[TBL] [Abstract][Full Text] [Related]
47. Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention.
Cameron MC; Lee E; Hibler BP; Giordano CN; Barker CA; Mori S; Cordova M; Nehal KS; Rossi AM
J Am Acad Dermatol; 2019 Feb; 80(2):321-339. PubMed ID: 29782901
[TBL] [Abstract][Full Text] [Related]
48. Vismodegib as an adjuvant treatment for periorbital basal cell carcinoma: a case report and review of literature.
Jabbehdari S; Veluvolu M; Kornhauser T; Jennings TA; Pemberton JD
Ann Transl Med; 2024 Jun; 12(3):54. PubMed ID: 38911557
[TBL] [Abstract][Full Text] [Related]
49. Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib.
Tang JC; Buckel L; Hanke CW
J Drugs Dermatol; 2019 Feb; 18(2):136-138. PubMed ID: 30794363
[TBL] [Abstract][Full Text] [Related]
50. Vismodegib for periocular basal cell carcinoma: an international multicentre case series.
Oliphant H; Laybourne J; Chan K; Haridas A; Edmunds MR; Morris D; Clarke L; Althaus M; Norris P; Cranstoun M; Sullivan TJ; Rajak SN
Eye (Lond); 2020 Nov; 34(11):2076-2081. PubMed ID: 31996838
[TBL] [Abstract][Full Text] [Related]
51. Vismodegib for Locally Advanced Basal Cell Carcinoma: Descriptive Analysis of a Case Series and Comparison to the Literature.
Viscusi KS; Hanke CW
J Drugs Dermatol; 2015 Sep; 14(9):956-62. PubMed ID: 26355613
[TBL] [Abstract][Full Text] [Related]
52. Epidermal cyst formation and hyperkeratosis in a patient treated with vismodegib for locally advanced Basal cell carcinoma.
Reinders MG; Brinkhuizen T; Soetekouw PM; Kelleners-Smeets NW; Hamid MA; Mosterd K
Acta Derm Venereol; 2015 May; 95(5):618-9. PubMed ID: 25425396
[No Abstract] [Full Text] [Related]
53. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
54. Mohs' micrographic surgery for basal cell carcinomas on the eyelids and medial canthal area. II. Reconstruction and follow-up.
Lindgren G; Lindblom B; Larkö O
Acta Ophthalmol Scand; 2000 Aug; 78(4):430-6. PubMed ID: 10990046
[TBL] [Abstract][Full Text] [Related]
55. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.
Bertrand N; Guerreschi P; Basset-Seguin N; Saiag P; Dupuy A; Dalac-Rat S; Dziwniel V; Depoortère C; Duhamel A; Mortier L
EClinicalMedicine; 2021 May; 35():100844. PubMed ID: 33997740
[TBL] [Abstract][Full Text] [Related]
56. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
[No Abstract] [Full Text] [Related]
57. Management of periocular basal cell carcinoma by Mohs micrographic surgery.
Litwin AS; Rytina E; Ha T; René C; Woodruff SA
J Dermatolog Treat; 2013 Jun; 24(3):232-4. PubMed ID: 22551161
[TBL] [Abstract][Full Text] [Related]
58. [What is new in basal cell carcinoma?].
Heppt M; von Braunmühl T; Berking C
Hautarzt; 2016 Nov; 67(11):876-883. PubMed ID: 27654826
[TBL] [Abstract][Full Text] [Related]
59. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
Zhu GA; Sundram U; Chang AL
JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
[TBL] [Abstract][Full Text] [Related]
60. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
